



ΟΣΦΕ



GREEK REPUBLIC

PANHELLENIC PHARMACEUTICAL ASSOCIATION



ΕΛΛΗΝΙΚΗ ΔΗΜΟΚΡΑΤΙΑ

ΠΑΝΕΛΛΗΝΙΟΣ ΣΥΛΛΟΓΟΣ ΦΑΡΜΑΚΑΠΟΘΗΚΑΡΙΩΝ Ν.Π.Δ.Δ.

To
the Minister of Health and Social Solidarity
Mr. An. Lykourentzos
Aristotelous 17
Athens

Cc
Deputy Minister of Health and Social Solidarity
Mr. M. Salmas
Deputy Minister of Health and Social Solidarity
Mrs. F. Skopouli

Protocol No. 256
Athens, 4 July 2012

Honorable Minister,

The target of the reduction of pharmaceutical expenditure has been served so far with consecutive measures, which have deregulated completely the pharmaceutical market and drive many companies throughout the supply chain to the limits of viability.

Within the framework of your upcoming meetings with the representatives of the Troika and in order to avoid a perception that would lead to wrong decisions, we would like to highlight the following:

- According to recent calculations by EOPYY, the efforts for the containment of pharmaceutical expenditure are within the targets set for 2012. Specifically, the total expenditure of Social Security Funds, following the deduction of the VAT and the implementation of all the

discounts and deductions re the hospital medicines and the real returns from pharmacies, is formed as follows:

Public Pharmaceutical Expenditure	Jan-12	Feb-12	Mar-12	Apr-12
Pharmaceutical Expenditure of EOPYY and other Social Security Funds	243.368.687	244.387.758	273.476.510	247.202.797

- Taking into consideration the fact that the pharmaceutical expenditure during May and June was reduced by 40%, the amount of total pharmaceutical expenditure for the first semester of 2012 will not exceed the amount of 1.400.000.000 having as a target the amount of 1.440.000.000.

Regarding the inclusion of VAT in the targeted amount of pharmaceutical expenditure, the VAT must not be included because, as mentioned to EOPYY's report re the debt, it constitutes not only an income but also an expense of the state distorting data on public finances.

- Therefore, we consider the obsession for implementation of supplementary measures (e.g. INN prescribing, Claw-back etc.) incomprehensible, given that the pharmaceutical sector is already one step before collapse. We highlight that the consequences of the up to now violent interventions in the supply chain have as basic recipients the Greek patients (and especially those suffering from chronic diseases) who are desperate in their effort to find even basic but essential medicines.

Honorable Minister,

We can overcome the ostensible impasse in the pharmaceutical sector in a way to achieve simultaneously on one hand the containment of the expenditure to the desired levels, without the slightest recession in the protection of public health, and on the other hand the healthy development of the supply chain.

Faithfully yours,

Konstantinos M. Frouzis
President, SFEE

Dimitrios Demos
President, PEF

Theodoros Ampatzoglou
President, PFS

Stavros Belonis
President, OSFE

Manolis Katsaris
President, PSF